Professor Steve Nissen, Cleveland Clinic, Ohio, USA, reviews progress with zerlasiran, including the Phase 1 APOLLO single and multiple ascending dose study in patients with elevated Lp(a) (≥ 150 nmol/L), and the Phase 2 ALPACAR trial in patients at high risk of atherosclerotic cardiovascular disease and with elevated Lp(a) ≥ 125 nmol/L
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
